natgillin/translations-raw huggingface dataset:
Infusions must be administered under the close supervision of an experienced physician with full resuscitation facilities immediately available (for radiopharmaceutical precautions see also sections ‘4.2 and 12’).
Infuzije je potrebno davati pod strogim nadzorom iskusnog liječnika uz trenutno dostupnu opremu za reanimaciju (mjere opreza vezane uz radiofarmaceutike potražite u dijelovima 4.2 i 12).
Infusions of blood products must not occur simultaneously with Voriconazole Hospira.
Infuzija krvnih pripravaka ne smije se odvijati u isto vrijeme s primjenom lijeka Vorikonazol Hospira.
Infusomat, Braun
Infusomat™, Braun
Ingestion
Ingestija
Ingestion
Ingestija lijeka
Ingestion of 100 mg oral oxybutynin chloride in association with alcohol has been reported in a 13 year old boy who experienced memory loss, and in a 34 year old woman who developed stupor, followed by disorientation and agitation on awakening, dilated pupils, dry skin, cardiac arrhythmia, and retention of urine.
Peroralni unos 100 mg oksibutininklorida zajedno s alkoholom prijavljen je kod 13-godišnjeg dječaka koji je imao gubitak pamćenja te kod 34-godišnje žene kod koje se je razvio stupor, nakon čega je uslijedila dezorijentiranost i agitiranost pri buđenju, proširene zjenice, suha koža, srčana aritmija i retencija urina.
Ingestion of 100 mg oral oxybutynin in association with alcohol has been reported in a 13 year old boy who experienced memory loss, and in a 34 year old woman who developed stupor, followed by disorientation and agitation on awakening, dilated pupils, dry skin, cardiac arrhythmia, and retention of urine.
Peroralni unos 100 mg oksibutinina zajedno s alkoholom prijavljen je kod 13- godišnjeg dječaka koji je imao gubitak pamćenja te kod 34-godišnje žene kod koje se je razvio stupor, nakon čega je uslijedila dezorijentiranost i agitiranost pri buđenju, proširene zjenice, suha koža, srčana aritmija i urinarna retencija.
Ingestion of ritonavir with food results in lower ritonavir exposure than ingestion in the fasted state.
Uzimanje ritonavira s hranom rezultira manjom izloženosti ritonaviru nego uzimanje na prazan želudac.
Ingestion of vortioxetine in the dose range of 40 to 75 mg has caused an aggravation of the following adverse reactions: nausea, postural dizziness, diarrhoea, abdominal discomfort, generalised pruritus, somnolence and flushing.
Primjena vortioksetina u rasponu doze od 40 mg do 75 mg prouzročila je pogoršanje sljedećih nuspojava: mučnine, posturalne omaglice, proljeva, abdominalne nelagode, generaliziranog pruritusa, somnolencije i crvenila uz osjećaj vrućine.
ingle dose
jednokratnoj dozi
ingle dose)/cobicistat (150 mg multiple doses)
doza)/kobicistat (150 mg, višekratne
Ingredients in the blue, immediate-release layer: maize starch, microcrystalline cellulose, edetate disodium, citric acid, stearic acid and colorant (Indigo Carmine E132, Aluminum lake).
Sastojci u plavom sloju s trenutnim oslobađanjem: kukuruzni škrob, mikrokristalična celuloza, dinatrijev edetat, citratna kiselina, stearatna kiselina i bojilo (indigo carmine aluminium lake (E132)).
ingrowing hairs
urasle dlake
ingrown toenails with or without infection
urasli nokti na nožnim prstima, s infekcijom ili bez nje
Inhalation anaesthetics
Inhalacijski anestetici
Inhalation gas
Plin inhalata
Inhalation gas.
Plin inhalata.
inhalation in the morning and 1 inhalation in the evening or inhalations in the morning or
inhalacija ujutro i 1 inhalacija navečer ili inhalacije ujutro ili
Inhalation of nebulised tobramycin produces high sputum concentrations and low plasma levels.
Inhalacija atomiziranog tobramicina dovodi do visokih koncentracija u sputumu , a niskih u plazmi.
Inhalation of the liquid nitrogen is dangerous.
Udisanje tekućeg kisika je opasno.
Inhalation of the vapour and contact with the skin and mucosa, particularly that of the eyes, must be avoided.
Udisanje pare i doticaj s kožom i sluznicom, naročito očiju, mora se izbjegavati.
Inhalation of the vapour and contact with the skin and mucous membranes, especially the eyes, must be avoided.
Udisanje pare i doticaj s kožom i membranama sluznice, naročito očiju, mora se izbjegavati.
Inhalation powder Inhalation powder Inhalation powder
Prašak za inhalaciju
Inhalation powder,
Prašak inhalata,
Inhalation powder, hard capsule (inhalation powder)
Prašak inhalata, tvrda kapsula (prašak inhalata)
Inhalation powder, pre-dispensed
Prašak inhalata, dozirani
Inhalation powder, pre-dispensed (Inhalation powder).
Prašak inhalata, dozirani (Prašak inhalata).
Inhalation use
dišne puteve Za primjenu u dišne puteve
Inhalation use
Prašak inhalata, dozirani
Inhalation use
Primjena u dišne putove
Inhalation use
U dišne puteve
Inhalation use
U dišne putove
Inhalation use
Udisanje uporabu.
Inhalation use
Za inhalaciju
Inhalation use
Za primjenu inhalacijom
Inhalation use
Za primjenu u
Inhalation use
Za primjenu u dišne puteve
Inhalation use
Za primjenu u dišne putove
Inhalation use
Za primjenu u dišne putove.
Inhalation use 2.4 ml
U dišne putove 2,4 ml
Inhalation use only
Samo za primjenu u dišne puteve
Inhalation use only
Samo za primjenu u dišne putove
Inhalation use only.
Samo u dišne putove.
Inhalation use only.
Samo za primjenu u dišne puteve.
Inhalation use only.
Samo za primjenu u dišne putove.
Inhalation use, ONCE DAILY
Za primjenu u dišne puteve, JEDANPUT NA DAN
Inhalation use, once daily
Za primjenu u dišne putove, jedanput na dan
Inhalation use, ONCE DAILY Read the package leaflet before use.
Za primjenu u dišne puteve, JEDANPUT NA DAN Prije uporabe pročitajte uputu o lijeku.
Inhalation use, ONCE DAILY Read the package leaflet before use.
Za primjenu u dišne putove, JEDANPUT NA DAN Prije uporabe pročitajte uputu o lijeku.
Inhalation use.
Inhalacija.
Inhalation use.
Primjena u dišne putove
Inhalation use.
Primjena u dišne putove.
Inhalation use.
U dišne putove
Inhalation use.
U dišne putove.
Inhalation use.
Udisanje uporabu.
Inhalation use.
Za primjenu u dišne putove.
Inhalation vapour, liquid
Para inhalata, tekucina
Inhalation vapour, liquid
Pare inhalata, tekućina
Inhalation vapour, liquid for dogs, 100% sevoflurane
Pare inhalata, tekućina za pse, 100% sevofluran
Inhalation vapour, liquid for dogs, 100% v/v sevoflurane
Sevohale para inhalata, tekućina za pse, 100% v/v sevofluran
Inhale
Udahnite
Inhale by mouth the full content of one ampoule in the morning, and one ampoule in the evening using the Tolero nebuliser handset.
Inhalirajte na usta ukupni sadržaj jedne ampule ujutro i jedne ampule navečer koristeći ručni atomizator Tolero.
Inhale the capsule – 1st breath:
Inhalirajte kapsulu – prvi udisaj:
Inhale the capsule – 2nd breath:
Inhalirajte kapsulu – drugi udisaj:
Inhale the contents of the capsule using the inhaler, with one or two breaths in.
Udahnite sadržaj kapsule uz pomoć inhalatora u jednom ili dva udaha.
Inhale the medicine
Udahnite lijek:
Inhale the medicine again by repeating Steps 7 and 8 to ensure you have emptied the capsule.
Ponovno udahnite lijek tako da ponovite korake 7 i 8 kako biste bili sigurni da ste ispraznili kapsulu.
Inhale the medicine again by repeating steps 8 and 9.
Ponovno udahnite lijek ponavljajući 8. i
Inhale the medicine again by repeating steps 8 and 9.
Ponovno udahnite lijek ponavljajući 8. i 9. korak.
Inhale the medicine again by repeating steps 9 and 10.
Ponovno udahnite lijek ponavljajući 9. i
Inhale the medicine:
Udahnite lijek:
Inhale with one long, steady, deep breath in.
Udahnite jednom dugo, ravnomjerno i duboko.
Inhale your medicine as follows:
Inhalirajte lijek kako slijedi:
Inhaled aclidinium bromide acts locally in the lungs to antagonise M3 receptors of airway smooth muscle and induce bronchodilation.
Inhalirani aklidinijev bromid djeluje lokalno u plućima kao antagonist M3 receptora glatkih mišića dišnih puteva i izaziva bronhodilataciju.
Inhaled aclidinium bromide acts locally in the lungs to antagonise M3 receptors of airway smooth muscle and induce bronchodilation.
Inhalirani aklidinijev bromid djeluje lokalno u plućima kao antagonist M3 receptora glatkih mišića dišnih putova i izaziva bronhodilataciju.
Inhaled antibiotics (if applicable)
Inhalacijski antibiotici (ako je primjenjivo)
Inhaled antibiotics if this is part of your treatment routine
Antibiotici za inhalaciju, ako su dio Vaše uobičajene terapije.
INHALED BETA AGONIST
INHALACIJSKI BETA AGONIST
INHALED BETA AGONIST
INHALACIJSKI BETA-AGONISTI
INHALED BETA AGONIST
INHALIRAJUĆI BETA-AGONISTI
INHALED BETA AGONISTS
INHALACIJSKI BETA AGONISTI
INHALED BETA AGONISTS
INHALACIJSKI BETA-AGONISTI
INHALED BETA AGONISTS
INHALIRANI BETA-AGONISTI
Inhaled bronchodilators
Inhalacijski bronhodilatatori
Inhaled corticosteroids can affect the normal production of steroid hormones in your body, particularly if you use high doses for a long time.
Inhalirani kortikosteroidi mogu utjecati na normalno stvaranje steroidnih hormona u Vašem tijelu, posebice ako dulje vrijeme primjenjujete visoke doze.
Inhaled nitric oxide therapy may cause an increase in methaemoglobin.
Terapija inhalacije dušikovog (II) oksida može dovesti do povećanja koncentracije methemoglobina.
Inhaled nitric oxide therapy may cause an increase in methaemoglobin.
Terapija inhalacije dušikovog (II) oksida može prouzročiti povećanje methemoglobina.
Inhaled nitric oxide therapy should be maintained at 5 ppm until there is improvement in the neonate’s oxygenation such that the FiO2 (fraction of inspired oxygen) < 0.60.
Terapija inhalacije dušikovog (II) oksida mora se održavati na razini od 5 ppm dok ne dođe do poboljšanja oksigenacije novorođenčeta tako da FiO2 (frakcija udahnutog kisika) bude < 0,60.
inhaled steroids, used to treat hay fever (allergic rhinitis):
inhalacijske steroide, primjenjuje se za liječenje peludne groznice (alergijski rinitis):
Inhaled/Nasal corticosteroids
Inhalirajući/nazalni kortikosteroidi
Inhaled/nasal corticosteroids: Budesonide, fluticasone
Inhalacijski/nazalni kortikosteroidi: Budezonid, flutikazon
inhaled/nasal fluticasone budesonide
Inhalacijski/za primjenu u
inhaler (plastic/ stainless steel)
inhalator (plastika
Inhaler base
Donji dio inhalatora
Inhaler Blister card Inhaler base
Inhalator Blister kartica Donji dio inhalatora
inhaler containing 120 doses. inhalers each containing 120 doses.
inhalator sa 120 doza. inhalatora, svaki sadrži 120 doza.
Inhaling medicines can cause chest tightness and wheezing and this can happen immediately after taking this medicine.
Lijekovi za inhalaciju mogu uzrokovati stezanje u prsima i piskanje (pri disanju), do čega može doći odmah nakon uzimanja lijeka.
Inhaling Ventavis might trigger breathing difficulties (see section 4), especially in patients with bronchospasm (sudden constriction of the muscles in the walls of the small airways) and wheezing.
Inhaliranje lijeka Ventavis može uzrokovati poteškoće s disanjem (pogledajte dio 4), osobito u bolesnika s bronhospazmom (iznenadno stezanje mišića u stijenkama malih dišnih putova) i piskanjem pri disanju.
inherent risk of inducing torsades
i inherentnog rizika od indukcije
Inherently resistant organisms
Mikroorganizmi s prirođenom rezistencijom
Inherently resistant organisms Mycobacterium xenopi Mycobacterium novocastrense Mycobacterium shimoidei
Prirođeno rezistentni mikroorganizmi Mycobacterium xenopi Mycobacterium novocastrense Mycobacterium shimoidei
Inherently resistant organisms:
Organizmi s urođenom rezistencijom:
inhibition
inhibicija
inhibition and
Mehanizam: ketokonazol i paritaprevir/
inhibition and CYP2C19 induction
CYP3A4 i indukcije CYP2C19
inhibition by
gemfibrozil
inhibition by
inhibicija
inhibition by
inhibicija ritonavirom.
inhibition by
Mehanizam: inhibicija CYP3A
inhibition by
Mehanizam: paritaprevir inhibira OATP1B
inhibition by
ombitasvir/paritaprevir/ri tonavir.
inhibition by
paritaprevir
inhibition by
PRIMIJE- NJEN UZ
inhibition by
ritonavirom te inhibicija
inhibition by indinavir)
(inhibicija CYP3A4 indinavirom)
inhibition by lopinavir/ritonavir,
inhibicije od strane
inhibition by lopinavir/ritonavir.
lopinavirom/ritonavirom.
inhibition by paritaprevir.
(1,05-1,25)
inhibition by paritaprevir.
inhibicija paritaprevir
inhibition by paritaprevir.
Smanjiti dozu pravastatina za 50%.
inhibition by ritonavir and increase in paritaprevir
ritonavirom, dok bi povećanje
Inhibition by ritonavir of transport protein-mediated uptake into hepatocytes and of CYP3A4, thereby reducing the clearance of bosentan, most likely causes this interaction.
Najvjerojatniji uzrok te interakcije je inhibicija ritonavirom transportnog proteina kojim se bosentan unosi u hepatocite te CYP3A4, reducirajući pritom klirens bosentana.
inhibition by ritonavir.
400/100 mg BID,
inhibition by ritonavir.
inhibicija ritonavirom.
inhibition by ritonavir.
Lanzoprazol
inhibition of
inhibicije
inhibition of
jedanput na
Inhibition of butyrylcholinesterase activity in CSF of 14 Alzheimer patients treated by oral rivastigmine was similar to the inhibition of AChE activity.
Inhibicija aktivnosti butirilkolinesteraze u cerebrospinalnoj tekućini 14 bolesnika s Alzheimerovom bolešću, koji su bili liječeni rivastigminom, bila je slična inhibiciji aktivnosti AChE- a.
Inhibition of butyrylcholinesterase activity in CSF of 14 Alzheimer patients treated by rivastigmine was similar to that of AChE.
Inhibicija aktivnosti butirilkolinesteraze u cerebrospinalnoj tekućini 14 bolesnika s Alzheimerovom bolešću, koji su bili liječeni rivastigminom, bila je slična inhibiciji aktivnosti AChE- a.
Inhibition of carbonic anhydrase in the ciliary processes of the eye decreases aqueous humour secretion, presumably by slowing the formation of bicarbonate ions with subsequent reduction in sodium and fluid transport.
Inhibicijom karboanhidraze u cilijarnim nastavcima oka smanjuje se lučenje očne vodice, pretežno usporavanjem stvaranja bikarbonatnih iona, s posljedičnim smanjenjem prijenosa natrija i tekućine.
Inhibition of CYP 2C9 with first- dose tipranavir/r, then induction of CYP 2C9 with steady-state tipranavir/r
Inhibicija CYP 2C9 prvom dozom tipranavira/r, zatim indukcija CYP 2C9 tipranavirom/r u stanju ravnoteže
Inhibition of CYP 2D6 by tipranavir/r
Inhibicija CYP 2D6 tipranavirom/r
Inhibition of CYP 2D6 by tipranavir/r
Inhibicija CYP 3A4 putem
Inhibition of CYP 3A4 by
Inhibicija CYP 3A4 putem
Inhibition of CYP 3A4 by
Inhibicija CYP 3A4 putem tipranavira/r
Inhibition of CYP 3A4 by tipranavir/r.
kontracepcijske mjere kad se oralni
Inhibition of CYP 3A4 by tipranavir/r.
kontracepcijske mjere kada se
Inhibition of CYP1A2:
Biotransformacija
Inhibition of CYP1A2:
epistaksa9
Inhibition of CYP1A2:
Inhibicija CYP1A2:
inhibition of CYP2D6 by
inhibicija CYP2D6 koju uzrokuje
inhibition of CYP3A
inhibicija CYP3A
inhibition of CYP3A and
inhibicija CYP3A i OATP
Inhibition of CYP3A and intestinal P-gp may lead to increased plasma levels and pharmacodynamic effects of rivaroxaban which may lead to an increased bleeding risk.
Inhibicija CYP3A i intestinalnog P-gp može dovesti do povećanih razina u plazmi i farmakodinamičkih učinaka rivaroksabana što može uzrokovati povećan rizik od krvarenja.
inhibition of CYP3A by
telaprevir inhibira CYP3A
inhibition of CYP3A,
inhibicija CYP3A,
Inhibition of CYP3A-mediated metabolism by cobicistat enhances the systemic exposure of CYP3A substrates (such as atazanavir or darunavir) that have limited oral bioavailability and a short half-life due to CYP3A-dependent metabolism.
Inhibicija metabolizma posredovanog CYP3A kobicistatom pojačava sistemsku izloženost supstratima CYP3A (kao što su atazanavir ili darunavir) koji imaju ograničenu peroralnu bioraspoloživost i kratki poluvijek zbog CYP3A ovisnog metabolizma.
Inhibition of CYP3A-mediated metabolism by cobicistat enhances the systemic exposure of CYP3A substrates, such as atazanavir, where bioavailability is limited and half-life is shortened by CYP3A- dependent metabolism.
Inhibicijom metabolizma u kojem posreduje CYP3A, kobicistat povećava sistemsku izloženost supstratima za CYP3A (poput atazanavira), koji zbog metabolizma ovisnog o CYP3A imaju ograničenu bioraspoloživost i kratak poluvijek.
Inhibition of CYP3A.
Inhibicija CYP3A.
Inhibition of CYP3A4 by aprepitant could result in elevated plasma concentrations of these active substances, potentially causing serious or life- threatening reactions.
Inhibicija CYP3A4 aprepitantom može povisiti koncentracije tih lijekova u plazmi, što može prouzročiti ozbiljne ili za život opasne reakcije.
Inhibition of CYP3A4 by aprepitant could result in elevated plasma concentrations of these active substances, potentially causing serious or life-threatening reactions.
Inhibicija CYP3A4 aprepitantom može povisiti koncentracije tih djelatnih tvari u plazmi, što može prouzročiti ozbiljne ili za život opasne reakcije.
inhibition of CYP3A4 by atazanavir and cobicistat.
inhibicija CYP3A4 koju uzrokuju
Inhibition of CYP3A4 by fosaprepitant could result in elevated plasma concentrations of these active substances, potentially causing serious or life- threatening reactions. (See section 4.3).
Inhibicija CYP3A4 fosaprepitantom može povisiti koncentracije tih lijekova u plazmi, što može prouzročiti ozbiljne ili za život opasne reakcije (vidjeti dio 4.3).
Inhibition of CYP450 isoenzyme CYP2C19 and CYP3A4 may provoke pharmacokinetic interactions (inhibition of their hepatic metabolism) with phenobarbital, primidone, phenytoin, carbamazepine, clobazam (see section 4.2), valproate (see section 4.2), diazepam (enhanced myorelaxation), ethosuximide, and tiagabine.
Inhibicija CYP450 izoenzima, CYP2C19 i CYP3A4 može izazvati farmakokinetičke interakcije (inhibiciju njihovog hepatičkog metabolizma) s fenobarbitalom, primidonom, fenitoinom, karbamazepinom, klobazamom (vidjeti dio 4.2), valproatom (vidjeti dio 4.2), diazepamom (pojačana miorelakscacija), etosuksimidom i tiagabinom.
Inhibition of factor Xa interrupts the intrinsic and extrinsic pathway of the blood coagulation cascade, inhibiting both thrombin formation and development of thrombi.
Inhibicijom faktora Xa prekida se unutarnji i vanjski put kaskadnog zgrušavanja krvi, čime se inhibira stvaranje trombina i razvoj tromba.
Inhibition of inflammation in Magnetic Resonance Imaging (MRI)
Inhibicija upale u magnetskoj rezonanciji (MR)
Inhibition of inflammation in sacroiliac (SI) joints as measured by MRI
Inhibicija upale u sakroilijačnim (SI) zglobovima mjereno pomoću MRI
Inhibition of joint structural damage was shown with significantly less radiographic progression in patients receiving tocilizumab compared to control (Table 3).
Inhibicija strukturalnih oštećenja zgloba očitovala se u značajno manjoj radiološkoj progresiji bolesti kod bolesnika koji su primali tocilizumab nego kod kontrolnih bolesnika (Tablica 3).
Inhibition of OATP1B1 cannot be ruled out and this has not been studied.
Inhibicija OATP1B1 ne može se isključiti i još nije ispitana.
Inhibition of OATP1B1/1B3 transporters by co-administration with rifampicin resulted in a 75% increase in Cmax and a 35% increase in AUC of empagliflozin.
Inhibicija prijenosnika OATP1B1/1B3 putem istodobne primjene s rifampicinom rezultirala je 75 %- tnim povećanjem vrijednosti Cmax i 35 %-tnim povećanjem vrijednosti AUC za empagliflozin.
Inhibition of OATP1B1/1B3 transporters by co-administration with rifampicin resulted in a 75% increase in Cmax and a 35% increase in AUC of empagliflozin.
Inhibicija prijenosnika OATP1B1/1B3 putem istodobne primjene s rifampicinom rezultirala je 75%- tnim povećanjem vrijednosti Cmax i 35%-tnim povećanjem vrijednosti AUC za empagliflozin.
Inhibition of P-gp and/or BCRP by lapatinib likely contributed to the increased exposure to pazopanib.
Povećanoj izloženosti pazopanibu vjerojatno je doprinijela inhibicija P-gpa i/ili BCRP-a lapatinibom.
Inhibition of platelet aggregation, platelet adhesion and release reaction
inhibicija agregacije trombocita, adhezija i reakcija otpuštanja trombocita
Inhibition of progression of structural damage in PsA has not yet been demonstrated using the subcutaneous loading regimen approved for clinical use.
Inhibicija progresije strukturalnog oštećenja u PsA-u nije dokazana korištenjem subkutanog režima doziranja odobrenog za kliničku primjenu.
Inhibition of prostaglandins by NSAIDs, including COX-2 inhibitors, may diminish the effect of angiotensin converting enzyme (ACE) inhibitors, angiotensin II antagonists, beta-blockers and diuretics.
Inhibicija prostaglandina nesteroidnim protuupalnim lijekovima, uključujući inhibitore COX-2 inhibitore, može umanjiti učinke inhibitora angiotenzin konvertirajućeg enzima (ACE), antagonista angiotenzina-II, beta blokatora i diuretika.
Inhibition of RANK/RANK ligand (RANKL) in animal studies has been coupled to inhibition of bone growth and lack of tooth eruption (see also section 5.3).
U ispitivanjima na životinjama inhibicija RANK/RANK liganda (RANKL) bila je povezana s inhibicijom rasta kosti i nedostatkom nicanja zubi (također vidjeti dio 5.3).
Inhibition of structural damage was maintained with Cosentyx treatment up to Week 52.
Inhibicija strukturalnog oštećenja održala se uz liječenje Cosentyxom do 52. tjedna.
Inhibition of the anticoagulant effect of warfarin, when given with 6–mercaptopurine, has been reported.
Zabilježena je inhibicija antikoagulantnog učinka varfarina pri istodobnoj primjeni sa 6- merkaptopurinom.
Inhibition of the key contributors of indacaterol clearance, CYP3A4 and P-glycoprotein (P-gp), raises the systemic exposure of indacaterol up to two-fold.
Inhibicija ključnih čimbenika koji pridonose klirensu indakaterola, CYP3A4 i P-glikoprotein (P-gp), podiže sistemsku izloženost indakaterola do dva puta.
Inhibition of these enzymes may lead to increased exposure of paclitaxel and hence increased toxicity of paclitaxel.
Inhibicija tih enzima može dovesti do povećane izloženosti paklitakselu i time do povećane toksičnosti paklitaksela.
inhibition of transport
inhibicija transportnih
Inhibition of XO by febuxostat may cause increased plasma concentrations of these drugs leading to toxicity (see section 4.4).
Inhibicija XO febuksostatom može uzrokovati porast koncentracije tih lijekova u plazmi, što dovodi do toksičnosti (vidjeti dio 4.4).
inhibition)
IMUNOSUPRESIVI
inhibition)
inhibicija P-gp-a)
inhibition)
uključujući inhibiciju CYP3A)
inhibition.
Nepoznati mehanizam.
inhibitor and substrate]
supstrat CYP3A4]
Inhibitor development in previously treated patients (PTPs) and in previously untreated patients (PUPs) has been reported.
Zabilježen je razvoj inhibitora u prethodno liječenih bolesnika (PTPs - previously treated patients) i u prethodno neliječenih bolesnika (PUPs - previously untreated patients).
Inhibitor development in previously untreated and treated patients (PUPs / PTPs) has been reported (see section 4.4).
Razvoj inhibitora zabilježen je u prethodno neliječenih i liječenih bolesnika (PNB / PLB) (vidjeti dio 4.4).
inhibitor drug plasma levels, depending on the protease inhibitors.
Učinak telaprevira na koncentracije ritonavirom pojačanog inhibitora proteaze u plazmi je heterogen, ovisno o inhibitorima proteaze.
inhibitor prescribing
interakcija lijeka.
inhibitor.
Za ove inhibitore
inhibitor]
P-glikoproteina]
inhibitors
na dan
inhibitors
pumpe
inhibitors (e.g. boosted PIs)
CYP3A (npr. pojačani IP) je
Inhibitors (ketoconazole, itraconazole, quinidine, verapamil, cyclosporine, erythromycin) and inducers (rifampicin, St John’s Wort) of these proteins may alter the exposure and/or distribution of lapatinib (see section 5.2).
Inhibitori (ketokonazol, itrakonazol, kinidin, verapamil, ciklosporin, eritromicin) i induktori (rifampicin, gospina trava) ovih proteina mogu promijeniti izloženost i/ili distribuciju lapatiniba (vidjeti dio 5.2).
Inhibitors are an uncommon event in previously treated patients (PTPs) receiving factor IX-containing products.
Razvoj inhibitora je manje česti događaj u prethodno liječenih bolesnika koji primaju lijekove koji sadrže faktor IX.
inhibitors is not recommended (see
preporučuje (vidjeti dio 4.4).
inhibitors may cause
uzrokovati miopatiju, uključujući
Inhibitors of ABCB1 and ABCG2 administered with oral topotecan have been shown to increase topotecan exposure.
Inhibitori ABCB1 i ABCG2 primijenjeni istovremeno s oralnim topotekanom povećavaju izloženost topotekanu.